- |||||||||| Tracleer (bosentan) / J&J, Roche
Journal: Hoarseness as a Rare Symptom of Idiopathic Pulmonary Arterial Hypertension Due to Ortner Syndrome: A Case Report. (Pubmed Central) - Mar 28, 2025
CONCLUSIONS This case report highlights the role of broad differential diagnosis of hoarseness, emphasizing rare cardiovascular diseases, such as IPAH. Hoarseness caused by the left recurrent laryngeal nerve palsy, resulting from pulmonary artery dilation, one of the most common Ortner syndrome causes, can be treated effectively with appropriate IPAH treatment, by reducing the diameter of the pulmonary trunk.
- |||||||||| Tracleer (bosentan) / J&J, Roche
Observational data, Retrospective data, Review, Journal: Doppler ultrasound, a noninvasive tool for the study of mesenteric arterial flow in systemic sclerosis: a cross-sectional study of a patient cohort with review and meta-analysis of the literature. (Pubmed Central) - Mar 27, 2025
3.508, p?=?0.001, respectively), but not with anticentromere antibody (ACA)...Vascular splanchnic involvement correlates with the presence and/or severity of specific clinical features in SSc, including GI. Larger and prospective studies are needed to confirm these preliminary observations and to examine the role of DUS in SSc-risk stratification and GI progression and to obtain definitive data regarding both HS and SSc patients splanchnic DUS parameters.
- |||||||||| Tracleer (bosentan) / J&J, Roche
Journal: Cocrystal pleomorphism-inspired drug nanoassembly for pulmonary-endothelium targeting and pulmonary hypertension treatment. (Pubmed Central) - Mar 5, 2025
Herein, inspired by the cocrystal pleomorphism theory, we prepared rod-shaped nanococrystals of the endothelin-1 (ET-1) receptor antagonist (bosentan, BST) and the anti-inflammatory drug (andrographolide, AG) for targeting the pulmonary endothelium and alleviating PH...In conclusion, the cocrystal-based strategy offers a promising approach for constructing co-delivery systems. The developed rod-shaped nanococrystals effectively target the pulmonary
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen, Tracleer (bosentan) / J&J, Roche
Journal: Systemic Sclerosis Complicated by Rapidly Progressive Osteomyelitis: A Case Report. (Pubmed Central) - Feb 12, 2025
This case highlights the critical need for vigilant radiographic monitoring and timely antibiotic intervention in patients with SSc who develop vascular complications. Early diagnosis and treatment are crucial for optimizing patient outcomes and preventing severe bone damage.
- |||||||||| methotrexate / Generic mfg., Tracleer (bosentan) / J&J, Roche
Preclinical, Journal: Inhibitory Effects of Alkaloids on OATP1B1 In Vitro and In Vivo: Prediction for Food/Herb-Drug Interactions and Hepatoprotective Effects Based on Structure-Activity Relationships. (Pubmed Central) - Feb 3, 2025
Four alkaloids, including dihydroberberine, deacetyltaxol, dihydrocapsaicin, and tetrahydropalmatine, significantly inhibited OATP1B1 transport activity in OATP1B1-HEK293 cells (>50%), which reduced the OATP1B1-mediated uptake of methotrexate and microcystin-LR, and consequently decreased their cell toxicity...The pharmacophore model suggested that the critical pharmacophores of alkaloid inhibitors are hydrogen bond acceptors and hydrophobic groups. Our findings pave the way for predicting the potential risks of alkaloids-containing food/herb-drug interactions in humans and optimizing the alkaloid structure for alleviating OATP1B1-related DILI.
- |||||||||| Adempas (riociguat) / Bayer, Merck (MSD), Opsumit (macitentan) / Nippon Shinyaku, J&J, Tracleer (bosentan) / J&J, Roche
Journal: A simple HPLC-UV method for monitoring therapeutic adherence in pulmonary arterial hypertension. (Pubmed Central) - Feb 2, 2025
For RIO, BOS and MAC, the developed method was suitable for both C0 and C3 samples, allowing steady-state drug determination if used. The presented method can be recommended to laboratories equipped with basic HPLC apparatus as an attractive analytical tool for both TDM and adherence studies.
- |||||||||| Opsumit (macitentan) / Nippon Shinyaku, J&J
Healthcare Resource Utilization and Progression in Patients with Pulmonary Arterial Hypertension Initiated on Monotherapy with Macitentan versus Other Endothelin-Receptor Antagonists (Poster Hall) - Jan 19, 2025 - Abstract #ISHLT2025ISHLT_2016;
During the study period, the other ERA cohort had higher PAH-related outpatient visits (1.04 vs 0.73 PPPM, IRR: 1.42), hospitalizations (0.06 vs 0.05 PPPM, IRR: 1.41), and re-hospitalizations within 30 days (0.01 vs 0.01 PPPM, IRR: 2.07) compared to the macitentan cohort (all p<0.05). In the KM analysis, numerically higher proportions of patients in the macitentan cohort were free of any progression endpoints at 6 months (80% vs 73%), 12 months (68% vs 61%), and 24 months (54% vs 49%).Conclusion In this retrospective US claims analysis, patients initiated on macitentan had lower PAH-related HRU and numerically longer time to progression compared to those on other ERA monotherapy.
- |||||||||| busulfan / Generic mfg.
Pulmonary Arterial Hypertension After Busulfan During Conditioning Regimen in Neuroblastoma: Key Role of Rescue Treatment (Poster Hall) - Jan 19, 2025 - Abstract #ISHLT2025ISHLT_284;
The patient showed progressive clinical, laboratory and imaging improvement. Genetic tests for PH-associated genetic mutations were negative.After 24 months of follow up, the patient showed NYHA functional class I, normal NTpro-BNP values, normal right ventricular dimension and function with physiological TR and normal PSVD at echocardiogram.Summary High clinical suspicion of PH in patients who have received Busulfan is recommended so that they are promptly referred to centers specializing in the management of childhood PH.
- |||||||||| Tracleer (bosentan) / J&J, Roche
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: EDIT-CAS: Efficacy of Endothelin Receptor Antagonism in Coronary Artery Spasm (clinicaltrials.gov) - Nov 18, 2024
P2/3, N=100, Enrolling by invitation,
Further research into drug-drug interactions involving endothelin receptor antagonists is warranted. Not yet recruiting --> Enrolling by invitation | Trial completion date: Apr 2026 --> Jul 2026 | Initiation date: Aug 2024 --> Nov 2024 | Trial primary completion date: Jan 2026 --> Jun 2026
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
A case of worsening scleroderma-associated interstitial lung disease in pregnancy () - Nov 8, 2024 - Abstract #BSRCBC2024BSR_CBC_67;
She was managed with mycophenolate mofetil, hydroxychloroquine, prednisolone, sildenafil, omeprazole, and vitamin D. During active disease phases with digital ulcerations, she received iloprost and bosentan.She had her first child aged 30 without complications while off mycophenolate mofetil...Her echocardiogram was normal with no evidence of pulmonary hypertension.Despite the increase in her prednisolone to 10 mg and the initiation of azathioprine, she continued to experience dyspnoea at rest...This suggests that tocilizumab may help stabilise inflammatory lung disease during pregnancy, indicating its potential use in managing severe maternal disease if other pregnancy-compatible drugs are not suitable. The decision to use tocilizumab in pregnancy involves careful consideration of the risks and benefits, with input from a multidisciplinary team to ensure comprehensive patient care.
- |||||||||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen, Tracleer (bosentan) / J&J, Roche, Rituxan (rituximab) / Roche
Echoes of Hope: Navigating Pregnancy post heart transplant in the context of systemic sclerosis () - Nov 8, 2024 - Abstract #BSRCBC2024BSR_CBC_11;
Previously, she was on Sildenafil, but this was discontinued due to developing non-ischemic optic neuritis and retinal vein thrombosis.Other complications secondary to SSc include oesophageal dysmotility, dyspepsia, and mild interstitial lung disease. Her medication history includes Bosentan, Losartan, Aspirin, Clopidogrel, Sertraline, Esomeprazole and multivitamins...MMF was switched to Azathioprine as part of her pregnancy planning...Patients should be monitored for arrhythmia and graft dysfunction due to postpartum volume shifts, although these changes are usually well tolerated.
- |||||||||| Tracleer (bosentan) / J&J, Roche
Journal: Pharmacoepidemiology of combination pulmonary vasodilator therapy in critically ill infants. (Pubmed Central) - Oct 16, 2024
Our study revealed an increased use of combination pulmonary vasodilator therapy, favouring inhaled nitric oxide and sildenafil, yet with considerable practice variation. Further research is needed to determine the optimal combination, sequence, dosing, and disease-specific indications for combination therapy.
- |||||||||| Adempas (riociguat) / Bayer, Merck (MSD), Opsumit (macitentan) / Nippon Shinyaku, J&J, Tracleer (bosentan) / J&J, Roche
Retrospective data, Review, Journal: An in-depth evaluation of the efficacy and safety of various treatment modalities for chronic thromboembolic pulmonary hypertension: A systematic review and network meta-analysis. (Pubmed Central) - Oct 14, 2024
Current therapeutic modalities are effective in terms of improving exercise capacity, pulmonary hemodynamics, and reducing adverse events and all-cause mortality. Overall, BPA and PADN were superior to all other targeted medications in the studied outcomes.
- |||||||||| Review, Journal: New and Emerging Therapeutic Drugs for the Treatment of Pulmonary Arterial Hypertension: A Systematic Review. (Pubmed Central) - Sep 30, 2024
Conversely, udenafil, racecadotril, sotatercept, anastrozole, riociguat, tacrolimus, and ralinepag were found to be safe, well-tolerated, and effective in improving hemodynamic measures and 6-MWDs. This study aims to summarize the developing treatment options currently under clinical trials, highlighting the need for further trials before their application in clinical practice.
- |||||||||| Retrospective data, Review, Journal: Pulmonary artery denervation versus conventional therapies for PAH: a systematic review and updated network meta-analysis. (Pubmed Central) - Sep 25, 2024
Compared with 16 types of conventional therapies and Placebo, PADN has advantage over nine single therapies and Placebo in improving 6MWD and appears to be better than two types of dual-drug combined therapies while with no statistical significance. PADN shows a favourable antihypertensive effect on mPAP and has a lower risk to trigger clinical worsening or hospitalization, while its risk on mortality and severe adverse events is still inconclusive.
- |||||||||| Tracleer (bosentan) / J&J, Roche
A MULTIFACETED APPROACH TO DYSPNEA IN CHRONIC LIVER CIRRHOSIS () - Aug 27, 2024 - Abstract #MTS2024MTS_263;
He was managed as liver cirrhosis with portal hypertension and started on Bosentan due to elevated pro-BNP levels...Despite being on low-dose prednisolone and azathioprine, full lung function testing showed normal spirometry but reduction in DLCO...Liver International. 2015 Jun; 35(6):1646-60.
- |||||||||| Saphnelo (anifrolumab-fnia) / AstraZeneca
Dramatic response to anifrolumab in refractory cutaneous systemic lupus (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2493;
Other treatments added for a better cutaneous control was dapsone with no improvement and mepacrine with partial control but abandoned for a marked yellow pigmentation... Early use of anifrolumab in moderate to severe cutaneous manifestations of systemic lupus may result in significant improvement in patients as in our case.
- |||||||||| Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
SAFETY AND EFFICACY OF SOTATERCEPT IN TREATING PULMONARY ARTERIAL HYPERTENSION: A SYSTEMATIC REVIEW (Convention Center Exhibit Hall: Poster Area 3) - Jul 31, 2024 - Abstract #CHEST2024CHEST_3932;
Ongoing research, such as the SOTERIA study, further supports Sotatercept's potential as a promising therapeutic option for PAH, but careful consideration of adverse effects is essential. We recommend more robust trials and longitudinal studies be conducted.
- |||||||||| Tracleer (bosentan) / J&J, Roche
SUSPECTED PLATYPNEA-ORTHODEOXIA IN A COMPLICATED EISENMENGER SYNDROME: RAPID DETERIORATION FOLLOWING RESPIRATORY ARREST (Convention Center Exhibit Hall: Poster Area 5) - Jul 31, 2024 - Abstract #CHEST2024CHEST_1731;
Although the exact mechanism of POS remains partially understood, its correlation with intracardiac and intrapulmonary shunts, occurring in the context of CHD such as VSD and PAH, implies a complex interaction of hemodynamic factors. The patient's rapid deterioration with suspected POS emphasizes the crucial need for careful management and preventing systemic volume depletion and hypotension, which can exacerbate right-to-left shunting resulting in hemodynamic instability.
- |||||||||| Tracleer (bosentan) / J&J, Roche
Journal: Effects of Bosentan on Hypoxia, Inflammation and Oxidative Stress in Experimental Blunt Thoracic Trauma Model. (Pubmed Central) - Jul 31, 2024
This suggests that bosentan may have protective effects on lung injury mechanisms by reducing hypoxia, inflammation, and oxidative stress. If supported by similar studies, bosentan can be used in both pulmonary and emergency clinics to reduce ischemic complications, inflammation, and oxidative stress in some diseases that may be accompanied by ischemia.
|
